PKD1-AS1: A Potential Drug Target and Biomarker (G105371049)

Target Name: PKD1-AS1

NCBI ID: G105371049

PKD1-AS1

Other Name(s): PKD1 antisense RNA 1

PKD1-AS1: A Potential Drug Target and Biomarker

PKD1-AS1 is a unique gene expression signature that has been identified in the plasma and urine of individuals with polycystic kidney disease (PKD). PKD is a genetic disorder that affects the kidney's ability to function, and individuals with PKD often experience a range of symptoms, including kidney failure, interstitial nephritis, and other chronic kidney diseases. PKD1-AS1 has been shown to be expressed in the kidneys of individuals with PKD, and it has been linked to the development and progression of PKD.

The discovery of PKD1-AS1 was made through a combination of genomic and transcriptomic approaches. Researchers used DNA sequencing to identify the signature gene expression profiles in the PKD1-AS1 gene cluster. They then used RNA sequencing to identify the specific RNA transcripts expressed in the PKD1-AS1 gene cluster. The results of these studies showed that PKD1-AS1 was expressed in the kidneys of individuals with PKD and that it was associated with the development and progression of PKD.

In addition to its association with PKD, PKD1-AS1 has also been shown to be a potential drug target. Studies have shown that inhibiting the activity of PKD1-AS1 has the potential to treat PKD by reducing inflammation and improving kidney function. This is because PKD1-AS1 has been shown to be involved in the development and progression of PKD by promoting inflammation and fibrosis in the kidneys.

The potential drug targets for PKD1-AS1 are still being explored, but they are an exciting area of research because they have the potential to revolutionize the treatment of PKD. One potential drug target for PKD1-AS1 is the inhibitor of the protein kinase B (PKB), which is known to be involved in the regulation of inflammation and fibrosis in the kidneys. Researchers have shown that inhibiting PKB activity with a small molecule inhibitor can protect against the development of PKD1-AS1-positive mice and improve kidney function in PKD1-AS1-positive mice.

Another potential drug target for PKD1-AS1 is the inhibitor of the NF-kappa pathway, which is involved in the regulation of cell growth and differentiation. Studies have shown that the NF-kappa pathway is involved in the development and progression of PKD, and that inhibiting NF-kappa activity with a small molecule inhibitor can protect against the development of PKD1-AS1-positive mice.

In addition to these potential drug targets, PKD1-AS1 has also been shown to be a potential biomarker for the diagnosis and progression of PKD. Studies have shown that PKD1-AS1 is expressed in the kidneys of individuals with PKD and that its expression is associated with the development and progression of PKD. This makes PKD1-AS1 an attractive biomarker for the diagnosis and prognosis of PKD.

Overall, the discovery of PKD1-AS1 is a significant finding that has the potential to revolutionize the treatment of PKD. The potential drug targets for PKD1-AS1 are still being explored, but they are an exciting area of research that has the potential to improve kidney function and quality of life for individuals with PKD.

Protein Name: PKD1 Antisense RNA 1

The "PKD1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PKD1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets